NCT04982276View on ClinicalTrials.gov

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

October 15, 2025

Study Completion Date

January 31, 2027

Conditions
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Interventions
BIOLOGICAL

AK109

Subjects will receive AK109 by intravenous administration.

DRUG

paclitaxel

Subjects will receive AK109 in combination with paclitaxel.

DRUG

paclitaxel

Subjects will receive AK104 and AK109 in combination with paclitaxel.

BIOLOGICAL

AK104

Subjects will receive AK104 by intravenous administration.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY